All In Biotech

Free tool

FAERS Monitor: Beqalzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220711 or its brand name (Beqalzi, Sonrotoclax). Reports on generic versions are filed under their own applications.

Reports

16

Serious

15

94% of reports

Hospitalization

7

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use7
  • acute kidney injury3
  • disease progression3
  • myelosuppression3
  • white blood cell count decreased3
  • neutrophil count decreased2
  • pneumonia2
  • rhinovirus infection2
  • acute myeloid leukaemia1
  • adverse event1
  • agranulocytosis1
  • anaemia1
  • arrhythmia1
  • atrial flutter1
  • back pain1

Reports by year received

View as table
YearReports
20256
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
rhinovirus infection2675.9184.8757
atrial flutter1164.724.740
myelosuppressionSignal3109.539.5224
acute myeloid leukaemia184.412.620
agranulocytosis170.710.617
neutrophil count decreased264.517.670
white blood cell count decreasedSignal336.413.171
disease progressionSignal333.312.065
arrhythmia127.84.26
acute kidney injurySignal325.89.349
adverse event114.32.13
off label useSignal710.56.053
pneumonia28.12.26
anaemia16.91.01
back pain15.70.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.